Natalizumab patent expiry eurasia ea patents?

When does natalizumab (Tysabri) patent protection expire in Eurasia?

Patent expiry dates across “Eurasia” depend on which country’s patent system applies and what kind of right is being counted (original patent vs. supplementary protection). The information provided here does not include any natalizumab patent-expiry timelines or specific Eurasian filings, so a precise expiration date can’t be determined from the available source material.

Which Eurasian jurisdictions matter for natalizumab patent expiry?

Users usually mean one or more of the following when they search “Eurasia”:
- Russia
- Kazakhstan
- Belarus
- Armenia
- Azerbaijan
- Georgia
- Kyrgyzstan
- Moldova
- Ukraine
- Tajikistan
- Turkmenistan
- Uzbekistan

Each has its own patent register and rules for terms, so the “expiry” date may differ by country even for the same drug and brand.

How to check the exact natalizumab patent expiry for each Eurasian country

To get the correct date for each jurisdiction, you typically need to look up:
1. The original substance/product patent(s) covering natalizumab (often multiple patents around composition, formulation, and therapeutic uses).
2. Any family member patents with later priority dates.
3. Whether any supplementary protection certificate (SPC) or equivalent extension mechanism exists and was granted.
4. Whether any court decisions or patent term adjustments affected enforceability.

In practice, analysts build a “patent landscape” and then identify which patents are still in force in each country.

Can biosimilars enter after patent expiry, or is there other exclusivity?

Even if a main patent expires, market entry can still be blocked by:
- Other still-in-force patents in the same family or related claims (e.g., specific therapeutic indications or methods).
- Regulatory and data exclusivity rules (which vary by jurisdiction).
- Litigation settlements that can delay launches.

So “patent expiry” alone doesn’t always equal “biosimilar launch allowed” in a given Eurasian country.

What name should you search for in Eurasian patent registers?

Patent databases may list natalizumab under:
- International Nonproprietary Name: natalizumab
- Brand: Tysabri
- Company/sponsor or assignee names associated with the drug’s originator
- Related therapeutic wording (multiple sclerosis, Crohn’s disease, etc.)

Searching by assignee and INN usually catches the relevant filings more reliably than searching only by brand.

If you share the countries, I can narrow to the exact expiry date(s)

If you tell me which Eurasian countries you mean (for example, “Russia + Kazakhstan” or “Eurasia = all former Soviet states”), I can focus the answer to those jurisdictions.